The development of anticytokine therapeutics for rheumatic diseases

Arthritis and Rheumatism

Volumn 58, Issue 2 SUPPL., 2008, Pages

  Arend, William P ^a,c   Goldring, Mary B ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UCDHSC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYTOKINE ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CELL COMMUNICATION; CLINICAL TRIAL; DRUG DESIGN; DRUG INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCIENTIFIC LITERATURE; SEPSIS;

ANIMALS; ANTIRHEUMATIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; INTERLEUKIN-1; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39549113500     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23053     Document Type: Review

References (63)

1. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
2. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
4. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-α/β, and IL-1Rα. Arthritis Rheum 1996;39:797-809.
5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
6. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor, structure, expression and homology to lymphotoxin. Nature 1984;212:724-9.
7. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984;312:721-4.
8. Bennett IL Jr, Beeson PB. Studies on the pathogenesis of fever. I. The effect of injection of extracts and suspensions of uninfected rabbit tissues upon the body temperature of normal rabbits. J Exp Med 1953;98:477-92.
9. Bennett IL Jr, Beeson PB. Studies on the pathogenesis of fever. II. Characterization of fever-producing substances from polymorphonuclear leukocytes and from the fluid of sterile exudates. J Exp Med 1953;98:494-508.
10. Atkins E, Wood WB Jr. Studies on the pathogenesis of fever. I. The presence of transferable pyrogen in the blood stream following the injection of typhoid vaccine. J Exp Med 1955;101:519-28.
11. Atkins E, Wood WB Jr. Studies on the pathogenesis of fever. II. Identification of an endogenous pyrogen in the blood stream following the injection of typhoid vaccine. J Exp Med 1955;102:499-516.
12. Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972;136:128-42.
13. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med 1972;136:143-55.
14. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A 1977;74:4624-7.
15. Dayer JM, Russell RGG, Krane SM. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 1977;195:181-3.
16. Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol 1979;123:2928-9.
17. Lomedico PT, Gubier U, Hellmann CP, Dulovich M, Giri JG, Pan YC, et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984;312:458-62.
18. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 1984;81:7907-11.
19. Fell HB, Jubb RW. The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum 1977;20:1359-71.
20. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1: purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985;162:1208-22.
21. Mizel SB, Dayer JM, Krane SM, Mergenhagen SE. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A 1981;78:2474-7.
22. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
23. Larrick JW. Native interleukin-1 inhibitors. Immunol Today 1989;10:61-6.
24. Dayer JM, Seckinger P. Natural inhibitors and antagonists of interleukin-1. In: RH Bomford, B Henderson, editors. Interleukin-1, inflammation and disease. Amsterdam: Elsevier Science Publishers; 1989. p. 283-302.
25. 2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 1986;78:1120-4.
26. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987;2:1240-2.
27. McGuire-Goldring MB, Meats JE, Wood DD, Ihrie EJ, Ebsworth NM, Russell RG. In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis Rheum 1984:27:654-62.
28. Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin or an inhibitor of interleukin 1. J Immunol 1985;134:3868-75.
29. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987;139:1546-9.
30. Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL-1 inhibitor from human monocytes: production and characterization of biological properties. J Immunol 1989;143:1851-8.
31. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40.
32. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6.
33. Carter DB, Deibel MR Jr, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8.
34. Arend WP. Interleukin 1 receptor antagonist: a new member of the IL-1 family. J Clin Invest 1991;88:1445-51.
35. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-225.
36. Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:31-45.
37. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor α. J Exp Med 1988;167:1511-16.
38. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, et al. Isolation and characterization of a tumor necrosis factor binding protein from human urine. Eur J Haematol 1989;42:270-5.
39. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80.
40. Mohler KM, Torrance DF, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF inhibitors. J Immunol 1993;151:1548-61.
41. Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004;25:201-9.
42. Brennen FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effects of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
43. Knight DM, Trinh H, Le J, Siegel S, Shealy S, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993:30:1443-53.
44. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
45. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned. Annu Rev Immunol 2001;19:163-96.
46. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007;104:11742-7.
47. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
48. Pascual V, Allantaz, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;210:1479-86.
49. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17:586-99.
50. Otero M, Goldring MB. Cells of the synovium in rheumatoid arthritis: chondrocytes. Arthritis Res Therapy 2007;9:220-32.
51. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Rev Immunol 2007;7:429-42.
52. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
53. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-11.
54. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323-40.
55. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004;2000:277-85.
56. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNFα therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 2007;204:33-9.
57. Peng SL. Translating regulatory T cells in rheumatoid arthritis: revisiting the past? [editorial]. Arthritis Rheum 2007;56:395-8.
58. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26.
59. Smolen J, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Rev Drug Discovery 2003;2:473-88.
60. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92.
61. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004;3:1-10.
62. Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:246-51.
63. Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:296-301.